Intervention not reported
Adverse effects · patients with rheumatoid arthritis
1 finding from 1 review
Intervention not reported
Discontinuation rates · patients with rheumatoid arthritis
1 finding from 1 review
Intervention not reported
Pain level Verbal pain scale. Scale from: 0 to 10. ( · patients with big toe joint osteoarthritis
1 finding from 1 review
Intervention not reported
Physical Function ‐ not measured · patients with big toe joint osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse effects ( · patients with big toe joint osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain Visual analog scale Scale from 0 to 100 (lower is better) · patients with Shoulder osteoarthritis
1 finding from 1 review
Disability/Function (ASES) American Shoulder and Elbow Surgeons Shoulder Score. Scale from: 0 to 100 (Higher is better). · patients with Shoulder osteoarthritis
1 finding from 1 review
Adverse Events‐Total (Intra‐operative and post‐operative) · patients with Shoulder osteoarthritis
Total Shoulder Arthroplasty showed no clear difference in adverse Events‐Total (Intra‐operative and post‐operative) compared with hemiarthroplasty (moderate certainty).
1 finding from 1 review
Rate of revision surgeries · patients with Shoulder osteoarthritis
Total Shoulder Arthroplasty showed no clear difference in revision Rate compared with hemiarthroplasty (moderate certainty).
1 finding from 1 review
Serious Adverse Events4 · patients with Shoulder osteoarthritis
1 finding from 1 review
Withdrawals due to adverse events · patients with Shoulder osteoarthritis
1 finding from 1 review
Intervention not reported
Pain (0‐10 cm visual analog scale)‐ Pain at 6‐12 weeks Visual Analog or Verbal Rating Scale. Scale from: 0 to 10. ( · patients with shoulder pain
1 finding from 1 review
Intervention not reported
Number of Adverse Events (AEs) ( · patients with shoulder pain
The intervention showed no clear difference in number of Adverse Events (AEs) ( (low certainty).
1 finding from 1 review
Intervention not reported
Disability/function ‐ not reported · patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
WIthdrawals due to Adverse Events ‐ not reported · patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Serious Adverse Events ‐ not reported · patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
ACR50% improvement criteria · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD leads to higher ACR50% improvement criteria compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
DAS (low or remission) · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD leads to higher DAS Remission defined as DAS28 <2.6 compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
HAQ improvement of >0.3 or MHAQ decrease of >0.22 (changes exceeding MCID) · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD leads to higher HAQ improvement of >0.3 or MHAQ decrease of >0.22 (changes exceeding… compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in serious Adverse Events compared with placebo + MTX/DMARD (moderate certainty).
1 finding from 1 review